4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Tinnitus by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 43 ongoing clinical trials involving Tinnitus
Of the 43 trials,23 trials are in Phase II
Furthermore, 8 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Tinnitus by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Tinnitus, an ear nose throat disorder. The largest number of ongoing clinical trials for Tinnitus is conducted in the Asia-Pacific region. North America and Middle East and Africa are among some of the other prominent regions engaged in Tinnitus-related drug trials.

Tehran University of Medical Sciences: The leading ongoing Tinnitus related clinical trial sponsor

Tehran University of Medical Sciences is the top sponsor for Tinnitus-related ongoing clinical trials.

Massachusetts Eye and Ear Infirmary, Otonomy Inc, NYU Langone Health System, and Isfahan University of Medical Sciences are among other notable clinical trial sponsors involved in Tinnitus. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Tinnitus

Vinpocetine (Cavinton), Betahistine dihydrochloride (Betaserc, Serc, Betaver, Vergo, Vertin, Evolis), and Adenosine (Adetphos-L) are among the key marketed drugs involving Tinnitus.

Vinpocetine (Cavinton) is a semisynthetic derivative of the vinca alkaloid. It functions via Phosphodiesterase 1 (PDE1 or EC 3.1.4.17) Inhibitor; Voltage Gated Sodium Channel (SCN) Blocker mechanism of action. It is formulated as tablet for oral route of administration and injection for intravenous route of administration. Vinpocetine is marketed for the treatment of Tinnitus and several other indications including Thrombosis, Dementia, Atherosclerosis, Hemorrhagic Shock, Stroke, Ischemic Stroke, Acute Sensorineural Hearing Loss, Choroiditis, Encephalopathy, Meniere Disease, and Vascular Dementias. Vinpocetine was first approved in 2008 and is marketed in China and Russia by Richter Gedeon Nyrt.

Betahistine dihydrochloride (Betaserc, Serc, Betaver, Vergo, Vertin, Evolis) is an anti-vertigo agent. It functions via Histamine H1 Receptor (HRH1) Agonist; Histamine H3 Receptor (G Protein Coupled Receptor 97 or GPCR97 or HRH3) Antagonist mechanism of action. It is formulated as tablet and solution for oral route of administration. It is indicated for the treatment of vertigo, emesis, tinnitus and hearing loss associated with Meniere's syndrome. Betahistine dihydrochloride was first approved in 1969 and is marketed globally including the UK, France, and Australia by Mylan BVBA, Abbott Laboratories, and LLC Veropharm.